Last updated on July 2019

A Study of LY3434172 a PD-1 and PD-L1 Bispecific Antibody in Advanced Cancer


Brief description of study

The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.

Clinical Study Identifier: NCT03936959

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.